India
oi-Ajay Joseph Raj P
New Delhi, Sep 19: In what comes as a recent development, the India trials of a vaccine candidate being developed by American company Novavax is likely to begin in late October, the government said in Lok Sabha on Friday.
It can be seen that the Novavax vaccine candidate is currently undergoing phase-2 clinical trials in South Africa. Global phase-3 trials are expected to begin next month. In India, Novavax has entered into an agreement with Pune-based Serum Institute of India for production of 100 million doses of the vaccine.
India’s COVID-19 tally surges past 5.3 million while recoveries stand at 4.2 million
Addressing the Parliament, Health Minister Dr Harsh Vardhan said, “ICMR and SII (Serum Institute of India) have partnered for clinical development of a…
